logo
ResearchBunny Logo
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Trastuzumab deruxtecan (T-DXd) has shown promising clinical advancements for patients with HER2+ gastric cancer, according to the DESTINY-Gastric01 trial. Engaging explorations into HER2 biomarkers and resistance mechanisms highlight correlations that could shape future therapies. This vital research was led by an exceptional team of authors.

00:00
00:00
Playback language: English
Abstract
Trastuzumab deruxtecan (T-DXd) showed statistically significant clinical improvement in patients with human epidermal growth factor receptor 2-positive (HER2+) gastric cancer in the DESTINY-Gastric01 trial. Exploratory analyses assessed baseline HER2-associated biomarkers in circulating tumor DNA and tissue samples, investigating mechanisms of resistance to T-DXd. Baseline HER2 biomarkers correlated with objective response rate (ORR) in the HER2+ cohort. Other key driver gene amplifications (MET, EGFR, FGFR2) were associated with numerically lower ORR. ORR was consistent regardless of immunohistochemistry sample collection timing. Further investigations are needed.
Publisher
Nature Medicine
Published On
Jul 01, 2024
Authors
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Yasuhiro Sakamoto, Tomohiro Nishina, Koichiro Inaki, Yusuke Kuwahara, Naoya Wada, Fumitaka Suto, Takeo Arita, Masahiro Sugihara, Zenta Tsuchihashi, Kaku Saito, Akihito Kojima, Kensei Yamaguchi
Tags
Trastuzumab deruxtecan
HER2-positive
gastric cancer
DESTINY-Gastric01 trial
biomarkers
resistance mechanisms
objective response rate
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny